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Abstract
Aims Activation of the renin–angiotensin–aldosterone system plays an important role in the pathophysiology of heart failure
(HF) and has been associated with poor prognosis. There are limited data on the associations of renin and aldosterone levels
with clinical profiles, treatment response, and study outcomes in patients with HF.
Methods and results We analysed 2,039 patients with available baseline renin and aldosterone levels in BIOSTAT-CHF (a sys-
tems BIOlogy study to Tailored Treatment in Chronic Heart Failure). The primary outcome was the composite of all-cause mor-
tality or HF hospitalization. We also investigated changes in renin and aldosterone levels after administration of
mineralocorticoid receptor antagonists (MRAs) in a subset of the EPHESUS trial and in an acute HF cohort (PORTO). In
BIOSTAT-CHF study, median renin and aldosterone levels were 85.3 (percentile25–75 = 28–247) μIU/mL and 9.4 (percentile25–
75 = 4.4–19.8) ng/dL, respectively. Prior HF admission, lower blood pressure, sodium, poorer renal function, and MRA treat-
ment were associated with higher renin and aldosterone. Higher renin was associated with an increased rate of the primary
outcome [highest vs. lowest renin tertile: adjusted-HR (95% CI) = 1.47 (1.16–1.86), P = 0.002], whereas higher aldosterone
was not [highest vs. lowest aldosterone tertile: adjusted-HR (95% CI) = 1.16 (0.93–1.44), P = 0.19]. Renin and/or aldosterone
did not improve the BIOSTAT-CHF prognostic models. The rise in aldosterone with the use of MRAs was observed in EPHESUS
and PORTO studies.
Conclusions Circulating levels of renin and aldosterone were associated with both the disease severity and use of MRAs. By
reflecting both the disease and its treatments, the prognostic discrimination of these biomarkers was poor. Our data suggest
that the “point” measurement of renin and aldosterone in HF is of limited clinical utility.
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Introduction
Activation of the renin–angiotensin–aldosterone system
(RAAS) plays a pivotal role in the development and subse-
quent progression of heart failure (HF); excessive and inap-
propriate RAAS activation may increase myocardial fibrosis
and favour the adverse myocardial remodelling.1,2 Renin
and aldosterone, as markers of RAAS activation, have been
associated with poor prognosis in previous studies.3–7 How-
ever, several clinical parameters such as severity of conges-
tion, cardiac and renal function, and HF treatments, e.g.
angiotensin converting enzyme inhibitor/angiotensin recep-
tor blocker (ACEi/ARBs), beta blockers, and mineralocorticoid
receptor antagonist (MRAs), may also influence the RAAS
activation.1,8,9
The systems BIOlogy study to Tailored Treatment in
Chronic Heart Failure (BIOSTAT-CHF) is a multicenter interna-
tional European project that assessed the factors associated
with under-prescription of life-saving therapies in HF and
the respective prognostic implications.10 The BIOSTAT-CHF
study allows for the unique opportunity to explore both the
prognostic value and the factors associated with activation
of the RAAS, reflected here by the determination of the circu-
lating levels of renin and aldosterone. We also measured re-
nin and aldosterone in a subset of patients of the
Eplerenone Post-Acute Myocardial Infarction Heart Failure Ef-
ficacy and Survival Study (EPHESUS) trial11 and in a cohort of
acute HF patients from Porto, Portugal.12
The aims of the present study are to investigate (i) the clin-
ical determinants of renin and aldosterone levels, (ii) the as-
sociation of renin and aldosterone with clinical outcomes,
and (iii) the discriminative prognostic value of renin and aldo-
sterone on top of the ‘best’ clinical model.
Methods
Patient population
The description of the BIOSTAT-CHF cohort has been previ-
ously published.10,13 In brief, BIOSTAT-CHF was an investiga-
tor-driven multicenter clinical study being consisted of
2,516 patients from 69 centres in 11 European countries with
symptoms of HF, which was confirmed by left ventricular
ejection fraction ≤40% and/or brain natriuretic peptide
>400 pg/mL or N-terminal pro BNP (NT-proBNP) >2,000
pg/mL and treatment of furosemide. From this cohort, we
analysed 2,039 patients with available data on renin and aldo-
sterone at baseline. Patients were receiving <50% of the tar-
get doses of at least one of ACEi/ARBs and beta blockers at
the time of inclusion. The first three months of treatment
were a treatment optimization phase. During the optimiza-
tion phase, initiation or uptitration of ACEi/ARB and/or beta
blocker was done according to the routine clinical practice
of the treating physicians, who were encouraged to follow
the European Society of Cardiology guideline.14
All patients recruited in BIOSTAT-CHF gave written in-
formed consent to participate in the study. BIOSTAT-CHF
was conducted in concordance with the declaration of Hel-
sinki, national ethics, and legal requirements, as well as rele-
vant EU legislation. The study was approved by national and
local ethics committees. All patients recruited in BIOSTAT-
CHF gave written informed consent to participate in the
study.
EPHESUS was designed to assess the effects of eplerenone
on morbidity and mortality in patients with a left ventricular
ejection fraction (LVEF) ≤40% after acute myocardial infarc-
tion who had signs and symptoms of HF or diabetes as previ-
ously published.11,15 Among 6,632 patients in the EPHESUS
trial, 360 and 366 patients had respectively available renin
and aldosterone measurements at screening, 1-month, 3-
month, and 6-month visits.
The PORTO study was a prospective, single-center, non-
randomized, open-label, and interventional study.12 Patients
presenting with acute HF (AHF) were assigned to either oral
spironolactone plus standard AHF care or standard AHF care
alone in a Portuguese tertiary hospital. We analysed 97 pa-
tients with available renin and aldosterone measurements
in the first 24 h and at Day 3 after admission. Spironolactone
was administrated after the first sample was collected.
Biomarkers
Plasma samples were measured at baseline, i.e. when pa-
tients with HF visited a medical service in a decompensated
state in BIOSTAT-CHF study. Patients could have come at
any time during the day, and they have had food before
the blood samples had been collected. All patients rested
for at least 15 min before collecting the samples. Renin and
aldosterone were both measured using a RadioImmunoAssay
(Renin: CisBio International; Aldosterone: IBL International) in
plasma samples that had previously undergone two freeze/
thaw cycles as previously published.16 For renin, the dynamic
range for this assay is 1.0 to 11,160 μIU/mL, and interassay
coefficients of variation were 5.0%. The direct renin assay
has been demonstrated to yield measurements that have a
high correlation with plasma renin activity and high reproduc-
ibility.17–19 The dynamic range for the aldosterone assay is
0.14 to 150 ng/dL, and interassay coefficients of variation
were < 7.5%. All the biomarkers were measured either at lo-
cal hospital site or within the BIOSTAT-CHF central laboratory.
Statistical analysis
Categorical variables are described as frequencies (percent-
ages), and continuous variables are described as means ±
2 M. Kobayashi et al.
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standard deviation or median (25th and 75th percentiles), de-
pending on the variable distributions. Comparisons of demo-
graphic, clinical, and biological parameters among tertiles of
renin and aldosterone levels were analysed using chi-squared
tests for categorical variables and Kruskal-Wallis test for con-
tinuous variables.
Linear regression analyses were performed to assess the
associations of clinical variables with renin and aldosterone
levels. Clinical variables were entered in the multivariable
model with forward selection. Covariates considered to be
of potential prognostic impact were age, sex, body mass in-
dex, medical history (diabetes mellitus, atrial fibrillation, pre-
vious myocardial infarction, prior HF admission, and chronic
obstructive pulmonary disease), HF etiologies (ischemic, hy-
pertensive, valvular heart disease, dilated cardiomyopathy,
and other), presence of signs and symptoms of congestion
(orthopnea, III heart sound, leg edema, and hepatomegaly),
systolic blood pressure (SBP), heart rate, LVEF, laboratory
findings [haemoglobin, sodium, potassium, blood urea nitro-
gen, and estimated glomerular filtration rate (eGFR) by the
Chronic Kidney Disease Epidemiology Collaboration for-
mula20], and treatments (use of ACEi/ARB, beta blockers,
and MRA). These variables had a small proportion of missing
values (<10%), and no multiple imputation was performed.
To assess the changes in renin and aldosterone levels after
the initiation of MRAs, repeated measures analysis of covari-
ance models were fit in terms of treatment group in the EPH-
ESUS and PORTO studies (eplerenone in the EPHESUS
substudy and spironolactone in PORTO study). Changes at
each time point were adjusted for baseline values and com-
pared between treatment groups.
The primary outcome was the composite of hospitalization
for HF or all-cause mortality. Secondary outcomes were all-
cause mortality and cardiovascular mortality. Survival proba-
bilities were estimated using the Kaplan–Meier method. The
covariates used for adjustment were chosen from demo-
graphic (age and sex), clinical (prior HF admission, use of beta
blockers, and SBP), and laboratory (NT-proBNP, blood urea
nitrogen, haemoglobin, high-density lipoprotein cholesterol,
eGFR, and sodium) parameters as previously published.21 All
parameters used to build the BIOSTAT-CHF risk models are
depicted herein (https://biostat-chf.shinyapps.io/calc/). In-
teractions between renin and aldosterone on clinical out-
comes were assessed using both continuous and categorical
variables. Curvilinear associations between log-transformed
baseline renin, aldosterone levels, and outcome were tested
using Cox models with unadjusted and adjusted for the
BIOSTAT-CHF risk models in a restricted cubic spline with five
knots. The added value of baseline renin and aldosterone
levels on the BIOSTAT-CHF risk model was assessed by means
of the increased c-index.
All analyses were performed using R version 3.4.0 (R Devel-
opment Core Team, Vienna, Austria). A two-sided P value
<0.05 was considered statistically significant.
Results
Baseline characteristics according to renin and
aldosterone levels
Among the 2,039 patients included in BIOSTAT-CHF study,
73% were male patients, mean age was 69 ± 12 years, and
mean LVEF was 31 ± 11% (Table 1). In the total cohort, me-
dian renin and aldosterone levels were 85.3 (IQR 28–247)
μIU/mL and 9.4 (IQR 4.4–19.8) ng/dL, respectively. The corre-
lation between renin and aldosterone was weak (Spearman
Rho = 0.28).
Patients with higher renin and aldosterone levels were
younger, more often male patients, had more often a prior
HF admission, lower SBP, lower LVEF, poorer renal function,
were less likely to receive target doses of ACEi/ARB, and were
more often prescribed MRAs (Table 1).
Clinical determinants of renin and aldosterone
levels
In the linear regression models, lower SBP, eGFR, sodium,
prior HF admission, no use of beta blocker, and MRA use
were the factors that were associated with both higher levels
of both renin and aldosterone (Table 2). Higher renin levels
alone were associated with higher body mass index, previous
myocardial infarction, chronic obstructive pulmonary disease,
and dilated cardiomyopathy. Higher aldosterone levels alone
were associated with no use of ACEi/ARB. The clinical vari-
ables associated with the highest tertiles of renin and aldo-
sterone are shown in Supporting Information, Table S1. The
associations of renin and aldosterone levels by the different
doses of ACEi/ARBs or MRAs are depicted in Table S2. Renin
and aldosterone levels were higher with the use of MRAs
and lower with increasing doses of ACEi/ARBs.
Effects of mineralocorticoid receptor antagonists
on renin and on aldosterone levels in EPHESUS
and PORTO cohort studies
In the EPHESUS substudy, eplerenone increased aldosterone
levels, and patients receiving eplerenone had higher renin
levels compared with placebo (Figure S1). Both changes
persisted thereafter. In addition, we observed that both renin
and aldosterone levels tended to increase after the initiation
of spironolactone in PORTO study (Figure S1).
Survival analysis
During a median follow up of 21 months, the primary out-
come occurred more frequently in patients with higher renin
Renin and aldosterone in patients with symptomatic heart failure 3
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levels (per each tertile increase; Figure 1). Similar results were
found in patients without MRA prescription (Figure S2). Com-
pared with the lowest tertile, the highest renin tertile was as-
sociated with an increased rate of the primary outcome
[adjusted-HR (95% CI) = 1.48 (1.25–1.76), P < 0.001] (Table
3). Concordantly, highest renin levels were associated with in-
creased rates of all-cause mortality and cardiovascular mor-
tality (Table S3). The association of renin levels with the
primary outcome after adjustment for the BIOSTAT-CHF risk
models using restricted cubic spline regression
analysis is shown in Figure 2. A log-normalized renin above
6.55 (= 700μIU/mL) was associated with a higher incidence
of the primary outcome.
Higher aldosterone levels were not associated with the pri-
mary outcome [adjusted-HR (95% CI) = 1.09 (0.92–1.28), P =
0.32] (Table 3). Similar results were found for all-cause and
cardiovascular mortality (Supporting Information, Figure S3).
There was no interaction between renin and aldosterone
on the primary outcome (P value > 0.1). As a sensitivity anal-
ysis, the associations of renin and aldosterone levels with the
primary outcome in ambulatory and hospitalized patients are
shown in Table S4. Furthermore, survival analyses for the pri-
mary outcome across European regions are also presented in
Table S5.
Renin and aldosterone on top of the BIOSTAT-CHF
risk model
Renin and aldosterone levels did not improve risk stratifica-
tion on top of the BIOSTAT-CHF risk model [for renin: in-
creased c-index (95% CI) = 0.28 (0.33–0.87), P = 0.37; for
aldosterone; 0.03 (0.05–0.102), P = 0.51] (Table 4). The dis-
criminative value of renin and aldosterone across baseline HF
treatment strata is shown in Table S6. A consistent absence
of discriminative value of renin and aldosterone was ob-
served across treatment strata.
Aldosterone-to-renin ratio
The median aldosterone-to-renin ratio (ARR) was 0.11 (IQR
0.03-0.31) (ng/dL)/(μIU/mL). Patients with lower ARR (driven
by higher renin levels) were more often male patients, had
more often cardiovascular comorbidities, lower SBP, LVEF, so-
dium concentrations, and poorer renal function, and were
more often prescribed ACEi/ARBs (Table S7). Compared with
the highest tertile, the lowest ARR was associated with an in-
creased rate of the primary outcome [adjusted-HR (95% CI) =
1.31 (1.11–1.55), P = 0.002] (Table S8) but did not improve
Table 2 Multivariable model for the associations of clinical profiles with renin and aldosterone levels in BIOlogy study to Tailored Treat-
ment in Chronic Heart Failure study
Variable
Renin Aldosterone
β 95% CI R2 = 0.26 P value β 95% CI R2 = 0.10 P value
(Constant) 21.69 19.28 to 24.09 <0.001 5.79 3.54 to 8.04 <0.001
Age, years (per 5 years) 0.04 0.07 to 0.01 0.004
Male 0.21 0.05 to 0.36 0.010
Body mass index, kg/m2 (per 5 kg/m2) 0.14 0.07 to 0.20 <0.001
Medical history
Myocardial infarction 0.33 0.14 to 0.53 0.001
Diabetes 0.14 0.27 to 0.03 0.018
Prior HF hospitalization 0.21 0.07 to 0.36 0.005 0.26 0.13 to 0.39 <0.001
Chronic obstructive pulmonary disease 0.28 0.10 to 0.46 0.003
HF etiologies*
Other (reference)
Ischemic heart disease 0.24 0.003 to 0.48 0.053
Hypertensive heart disease 0.13 0.41 to 0.15 0.37
Valvular heart disease 0.27 0.03 to 0.57 0.08
Dilated cardiomyopathy 0.31 0.08 to 0.54 0.007
Physical examination
III heart sound 0.24 0.03–0.44 0.025
Systolic BP, mmHg (per 10 mmHg) 0.20 0.23 to 0.16 <0.001 0.06 0.09 to 0.04 <0.001
Laboratory
Haemoglobin, g/dL 0.14 0.10 to 0.17 <0.001
eGFR, mL/min/1.73 m2 (per 5 mL/min/1.73 m2) 0.04 0.06 to 0.03 <0.001 0.03 0.05 to 0.02 <0.001
Sodium, mmol/L 0.11 0.13 to 0.09 <0.001 0.03 0.04 to 0.01 0.001
Medication
ACEi/ARB 0.27 0.41 to 0.13 <0.001
Beta blocker 0.33 0.51 to 0.14 <0.001 0.21 0.37 to 0.04 0.014
MRA 0.33 0.19 to 0.53 0.001 0.23 0.11 to 0.36 <0.001
Renin and aldosterone levels were expressed by natural logarithm transformation.
*Other aetiology was considered as the reference group among HF etiologies.
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BP, blood pressure; CI, confidence interval; eGFR, esti-
mated glomerular filtration rate; HF, heart failure; MRA, mineralocorticoid receptor antagonist.
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risk stratification on top of the BIOSTAT-CHF risk model [in-
creased c-index (95% CI) = 0.15 (0.25–0.55), P = 0.47].
Discussion
In patients with symptomatic HF, we assessed the clinical de-
terminants and prognostic implications of baseline renin and
aldosterone levels. Our main findings are as follows: (1)
higher baseline renin and aldosterone levels were associated
with HF severity, worse symptoms, poorer renal function and
were influenced by treatment with ACEi/ARBs, beta blockers,
and MRAs; (ii) higher renin but not aldosterone was indepen-
dently associated with poor prognosis; (iii) renin and
aldosterone levels did not improve risk stratification on top
of the ‘best’ BIOSTAT-CHF prognostic models; and (iv) initia-
tion of MRAs was associated with increased levels of renin
and aldosterone in the EPHESUS substudy and in an AHF co-
hort (PORTO).
Clinical determinants of renin–angiotensin–
aldosterone system activation
In response to a decrease in baroreceptor stretch, a rise in re-
nin levels ultimately result in sodium and water retention by
triggering sequential activation of peptides in the RAAS cas-
cade such as angiotensin II and aldosterone.22–24 Angiotensin
Figure 1 Survival curves for the primary outcome according to renin and aldosterone levels in BIOlogy study to Tailored Treatment in Chronic Heart
Failure study.
Table 3 Cox proportional hazards models of renin and aldosterone levels for the primary outcome in BIOlogy study to Tailored Treatment
in Chronic Heart Failure study
Univariable model Multivariable model
HR (95 % CI) P value HR (95% CI) P value
Renin
Continuous 1.20 (1.16–1.25) <0.001 1.11 (1.06–1.15) <0.001
Tertiles Low (reference) (reference)
Intermediate 1.34 (1.12–1.61) 0.001 1.17 (0.98–1.41) 0.08
High 2.01 (1.70–2.38) <0.001 1.48 (1.25–1.76) <0.001
Aldosterone
Continuous 1.01 (0.96–1.07) 0.58 1.02 (0.97–1.07) 0.53
Tertiles Low (reference) (reference)
Intermediate 0.96 (0.82–1.13) 0.65 1.10 (0.93–1.29) 0.28
High 1.05 (0.89–1.24) 0.55 1.09 (0.92–1.28) 0.32
Interaction between
renin and aldosterone
Continuous
Categorical
0.06
0.08
0.14
0.13
Renin and aldosterone levels as continuous variables were expressed by natural logarithm transformation.
CI, confidence interval; HR, hazard ratio.
Renin and aldosterone in patients with symptomatic heart failure 7
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.12634
II and aldosterone may also play a crucial role in promoting
kidney damage by regulating inflammation and reparative
processes that follow the tissue fibrosis.25–27 These mecha-
nisms may explain our observations that high renin and aldo-
sterone levels were associated with lower SBP, lower sodium
levels, and poorer renal function.3–5,8,28 In addition, previous
studies have shown that renin was overexpressed in visceral
and perivascular adipose tissue in an obese population, which
may explain the association between renin and body mass in-
dex in the present study.29,30 A prior HF admission and spe-
cific HF etiologies, e.g. patients with an ischemic aetiology
or dilated cardiomyopathy (particularly the latter), may partly
contribute to progression of ventricular remodelling,31–33
resulting in a higher degree of (excessive) RAAS activation.1,34
Circulating levels of renin and aldosterone are also influ-
enced by HF treatment. Renin is upregulated in response to
activation of the sympathetic nervous system,35 hence
explaining the association between beta blocker treatment
and lower renin and aldosterone levels.36 Moreover, the cur-
rent analysis also showed the association of higher doses of
ACEi/ARB with lower aldosterone, suggesting that despite
the aldosterone ‘escape’ phenomenon,37,38 a chronic de-
crease of aldosterone levels in patients taking ACEi/ARB ther-
apy may occur. On the other hand, increased renin and
aldosterone levels in patients treated with MRAs are consis-
tent with previous reports.4,5,39,40 This is likely related to an
increase in angiotensin II via feedback mechanisms of the
RAAS cascade or by direct regulation of aldosterone synthase
by MRA treatment.28,41,42 Indeed, the present analysis
showed continuous increases in renin and aldosterone after
administration with MRAs.
Association of renin and aldosterone with
outcomes
Median baseline levels of renin (85.3 μIU/mL) and aldoste-
rone (9.4 ng/dL) in this cohort were lower than in other re-
cent reports,3,5,28,43,44 potentially being influenced by the
relative clinical stability and insufficient blockage of RAAS cas-
cade in the current study. We show that renin (but not aldo-
sterone) was associated with the primary outcome (all-cause
Figure 2 Restricted cubic spline regression for the associations of renin or aldosterone with the primary outcome in BIOlogy study to Tailored Treat-
ment in Chronic Heart Failure study.
Table 4 Discrimination of renin and aldosterone levels for the primary Outcome in BIOSTAT-CHF study
c-index (95% CI) P value Increased c-index P value
Renin model BIOSTAT-CHF risk model 76.5 (74.5 to 78.6) <0.001
+ Renin 76.8 (74.7 to 78.8) <0.001 0.27 (0.33 to 0.87) 0.37
Aldosterone model BIOSTAT-CHF risk model 76.5 (74.5 to 78.6) <0.001
+ Aldosterone 76.5 (74.5 to 78.6) <0.001 0.03 (0.05 to 0.102) 0.51
C-statistic was calculated to compare the discriminatory power to predict primary outcome of baseline renin and aldosterone levels on top
of the BIOSTAT-CHF risk model. Renin and aldosterone levels as continuous variables are expressed by natural logarithm transformation.
BIOSTAT-CHF, BIOlogy study to Tailored Treatment in Chronic Heart Failure; CI, confidence interval.
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mortality and/or HF admission). Studies examining the prog-
nostic value of these biomarkers in the field of HF have
yielded conflicting results. In a post hoc analysis of EVEREST,
aldosterone levels were assessed in 1,850 placebo-treated
patients with AHF and a LVEF≤40%.3 During a median follow
up of 9.9 months (during which 19.0% of patients died), the
highest quartile of aldosterone was significantly associated
with higher incidence of all-cause mortality. A post hoc anal-
ysis of diuretic optimization strategies in acute heart failure
and cardiorenal rescue study in acute decompensated heart
failure assessed renin and aldosterone at baseline in 427 pa-
tients with AHF.5 Within 60 days, 6% patients died, and 30%
were hospitalized. Renin and aldosterone were not associ-
ated with the composite outcome of death or HF rehospital-
ization. A recent report of the Aliskiren Trial on Acute Heart
Failure Outcomes (ASTRONAUT) assessed baseline renin in
1,306 patients in both the aliskiren and placebo arms.4 Here,
increasing renin levels were associated with poorer progno-
sis. In the Valsartan Heart Failure Trial,45 baseline renin level
was associated with a higher incidence of mortality, while al-
dosterone was not. This is in line with findings of several
smaller observational studies.6,7,46 To the best of our knowl-
edge, our study is first to assess the (lack of) prognostic value
of renin and aldosterone on top of a well-calibrated risk
model. By demonstrating a lack of discriminatory prognostic
improvement, our findings suggest a limited prognostic utility
of renin and aldosterone.
Clinical implications
In the present analysis, we demonstrated that renin and aldo-
sterone levels were mainly associated with the patients’ clin-
ical severity (e.g. prior HF admission, lower SBP, sodium
concentration, and poorer renal function) and by the used
therapies (e.g. ACEi/ARB and MRAs) in consistency with the
existing literature. Importantly, these biomarkers do not im-
prove risk prediction on top of an already well-performing
clinical risk score. Furthermore, there was a consistent lack
of discriminative value of renin and aldosterone levels across
HF treatment regimens or different European regions. Conse-
quently, a ‘point’ measurement of renin and aldosterone
levels in patients with decompensated HF should be of clini-
cally limited utility.
Limitations
Our study has several limitations. This is a post hoc analysis of
the BIOSTAT-CHF; hence, the limitations inherent to observa-
tional data are present herein, and causality cannot be in-
ferred. By design, BIOSTAT-CHF enrolled patients not on
optimal guideline medical therapy. Although this condition
is frequent, results may not be generalizable to patients on
optimal therapy. All renin and aldosterone samples were fro-
zen and thawed with a same number of freeze/thaw cycles. It
may be associated with increased level of renin.47,48 How-
ever, renin level in this study was lower than that in previous
reports18,28,43,44; the effect of freeze/thaw cycles therefore
may be limited.
Conclusions
Renin and aldosterone activation were associated with both
the patients’ poor clinical condition (neurohormonal activa-
tion) and HF treatments (feedback mechanism). Renin and/
or aldosterone did not improve risk stratification. These find-
ings suggest that the ‘point’ measurement of these bio-
markers in patients with HF is of limited utility, both for
ascertaining the patients’ clinical condition and prognosis
(as they may reflect both the disease severity and the use
of life-saving therapies).
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